Multicenter Automatic Defibrillator Implantation Trial–Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol

Valentina Kutyifa, Christopher Beck, Mary W. Brown, David Cannom, James Daubert, Mark Estes, Henry Greenberg, Ilan Goldenberg, Stephen Hammes, David Huang, Helmut Klein, Reinoud Knops, Mikhail Kosiborod, Jeanne Poole, Claudio Schuger, Jagmeet P. Singh, Scott Solomon, David Wilber, Wojciech Zareba, Arthur J. Moss

Research output: Contribution to journalArticlepeer-review

Abstract

Patients with diabetes mellitus, prior myocardial infarction, older age, and a relatively preserved left ventricular ejection fraction remain at risk for sudden cardiac death that is potentially amenable by the subcutaneous implantable cardioverter defibrillator with a good risk-benefit profile. The launched MADIT S-ICD study is designed to test the hypothesis that post–myocardial infarction diabetes patients with relatively preserved ejection fraction of 36%-50% will have a survival benefit from a subcutaneous implantable cardioverter defibrillator.

Original languageEnglish
Pages (from-to)158-166
Number of pages9
JournalAmerican Heart Journal
Volume189
DOIs
StatePublished - 1 Jul 2017
Externally publishedYes

Fingerprint

Dive into the research topics of 'Multicenter Automatic Defibrillator Implantation Trial–Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol'. Together they form a unique fingerprint.

Cite this